EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors

NCT01251926 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

NIH

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: EZN-2208
DRUG: Bevacizumab

Sponsor

National Cancer Institute (NCI)